Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The aims of this talk
3. Why we are interested in imaging in epilepsy
4. Imaging commission of ILAE
5. Who should undergo imaging?
6. Indications for MRI
7. How should imaging be best done?
8. MRI epilepsy protocol
9. What the main findings are
10. "CT normal" localisation-related epilepsies
11. The most common "pathology" is normal MRI
12. Size of the problem: yield of high resolution MRI
13. The aims of this talk (2)
14. What is PET?
15. How does PET work: positron
16. How does PET work: radioactive isotopes
17. How does PET work: emission
18. How does PET work: tomography
19. What PET can be used for
20. What PET can be used for: metabolic tracers
21. Aims: defining the epileptogenic zone
22. Epileptogenic lesion
23. FDG and FMZ PET in normal MRI TLE
24. Volume loss or receptor change?
25. FMZ changes in TLE
26. FMZ-PET: involvement of the insula
27. Prediction of outcome
28. Is 11C-Flumazenil-PET clinically useful?
29. Imaging co-morbidities
30. Imaging genetics
31. Ictal 18F-Dopa-PET
32. Pitfalls: clinical (functional) imaging (1)
33. Pitfalls: clinical (functional) imaging (2)
34. Seizure onset zone
35. Extratemporal seizure onset
36. Ictal symptomatogenic zone
37. FDG - PET: correlation with ictal symptoms (1)
38. FDG - PET: correlation with ictal symptoms (2)
39. Irritative zone
40. Diprenorphine binding in MCD
41. NMDA receptors: 11C-CNS5161
42. FMZ-PET: involvement of the basal ganglia
43. Focal epilepsies
44. Ictal onset or symptomatogenic zone
45. Summary: molecular imaging in epilepsy

Topics Covered

• What is PET and how does it work
• What can PET be used for?
• The clinical impact of PET
• The epileptogenic zone
• Epileptogenic lesion
• Functional deficit zone
• Irritative zone
• Seizure onset zone
• Ictal symptomatogenic zone
• Imaging co-morbidities
• Imaging genetics

Links

Series:

• Epilepsy and Seizures
• Neurotrauma

Categories:

• Methods
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on November 1, 2011

Financial Disclosures

• Prof. Matthias Koepp has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.